Pancreatic cancer carries a dismal prognosis, with a median survival of less than six months following progression on standard chemotherapy. Precision oncology initiatives have historically benefited only a minority of patients, leaving systemic chemotherapy as the default standard of care for most. Recently, however, the RASolute302 trial demonstrated that daraxonrasib, a RAS(ON) multiselective inhibitor, significantly extends survival in the second-line setting compared with standard chemotherapy. <\/p>\n
The RASolute302 trial was a randomized, open-label, phase III study evaluating previously treated patients with metastatic pancreatic adenocarcinoma harboring KRAS G12, G13, or Q61 mutations and also wild-type disease. Patients were randomly assigned to receive either daraxonrasib or investigator\u2019s choice chemotherapy. The trial demonstrated an unprecedented improvement in overall survival. In the KRAS G12 cohort, median OS reached 13.2 months with daraxonrasib compared to 6.6 months with standard chemotherapy (HR 0.40; 95% CI, 0.30\u20130.54). Daraxonrasib also significantly prolonged progression-free survival, increased the objective response rate and improved quality of life. <\/p>\n
While these results are highly impressive and demonstrate a more favorable overall tolerability profile than chemotherapy, treatment with daraxonrasib was associated with notable toxicity; 43.6% of patients experienced grade 3 or higher treatment-related adverse events, most frequently rash (85.5%), diarrhea (58.1%), mucositis (53.1%), nausea (46.5%), and vomiting (36.9%).<\/p>\n
These landmark data establish daraxonrasib as the new standard of care for pretreated metastatic pancreatic adenocarcinoma. More broadly, these results usher in a transformative era in patient management and mark an inflection point in treatment innovation. Moving forward, several KRAS inhibitors are being evaluated as monotherapies or within combination regimens in the front-line setting. These combinations, including chemotherapy-free regimens, are poised to fundamentally reshape the treatment landscape over the coming years. <\/p>\n